Kadcyla (Ado-Trastuzumab Emtansine)
Brand Names: Kadcyla
Methodology & AI Transparency ⓘ
Kadcyla (Ado-Trastuzumab Emtansine) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within the FDA Prescription Therapeutic Agent category, Kadcyla provides branded delivery of active moiety Ado-Trastuzumab Emtansine (cross-referenced at /meds/ado-trastuzumab-emtansine) (registered by Genentech, Inc.; NDC 50242-087, 50242-088).
- 2 Real-world patient consensus: Registered under RxNorm 1658087 and SPL 2026-04-01, pairing Kadcyla packaging with active ingredient Ado-Trastuzumab Emtansine.
- 3 Typical cash cost range: Public pharmacy ledger: $31.54 low cash benchmark vs. $83.58 chain retail average ($0.3200/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Kadcyla (Ado-Trastuzumab Emtansine): nausea (9.6%), headache (11.8%), fatigue (7.3%).
Ask our AI Specialists anything about Kadcyla (Ado-Trastuzumab Emtansine)
Kadcyla (Ado-Trastuzumab Emtansine) Mechanism, CYP450 Pathways & DailyMed Monograph
Within the FDA Prescription Therapeutic Agent category, Kadcyla provides branded delivery of active moiety Ado-Trastuzumab Emtansine (cross-referenced at /meds/ado-trastuzumab-emtansine) (registered by Genentech, Inc.; NDC 50242-087, 50242-088). Characterized by 20 mg/mL Injection, Powder, Lyophilized, for Solution; 5% under 2026-04-01 SPL documentation, Kadcyla targets 1 Indications and usage kadcyla: is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single.
Through its Ado-Trastuzumab Emtansine active moiety, Kadcyla exerts fda prescription therapeutic agent activity involving CYP3A4 clearance pathways. Registered under NDC 50242-087, 50242-088 (registered by Genentech, Inc.; effective 2026-04-01), the 20 mg/mL Injection, Powder, Lyophilized, for Solution; 5% presentation ensures reproducible pharmacokinetic release profiles documented in federal RxNorm (1658087) and CMS NADAC ($0.3200/unit) ledgers.
Systemic exposure to Kadcyla (Ado-Trastuzumab Emtansine) reflects Complete (~100%) parenteral systemic delivery for Kadcyla (Ado-Trastuzumab Emtansine) (20 mg/mL Injection, Powder, Lyophilized, for Solution) absorption kinetics and hepatic oxidation via cyp3a4 followed by renal and biliary excretion of kadcyla (ado-trastuzumab emtansine) metabolites, sustaining receptor engagement across a Approximately 9–13 hours terminal plasma half-life for Kadcyla (Ado-Trastuzumab Emtansine) half-life window (rapid intravascular/parenteral onset within 15–45 minutes after kadcyla (ado-trastuzumab emtansine) administration response profile).
Dosing protocols (20 mg/mL Injection, Powder, Lyophilized, for Solution or 5%) balance efficacy (83.00% patient satisfaction across 20 logs) against headache (11.8% of reports), nausea (9.6% of reports), constipation (7.7% of reports), with strict avoidance in severe drug-induced hypersensitivity to ado-trastuzumab emtansine or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2026-04-01 for kadcyla (ado-trastuzumab emtansine).
Inhibiting CYP3A4 clearance during Kadcyla (Ado-Trastuzumab Emtansine) therapy increases concentration-dependent adverse effects.
Review concurrent CYP3A4 substrates and inhibitors when titrating Kadcyla (Ado-Trastuzumab Emtansine) maintenance doses.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Ado-Trastuzumab Emtansine or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2026-04-01 for Kadcyla (Ado-Trastuzumab Emtansine)
Logged Side-Effect Incidence (20 Reports)
Kadcyla (Ado-Trastuzumab Emtansine) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Kadcyla (Ado-Trastuzumab Emtansine))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Efficacy, Safety, how the body absorbs the medicine and Immunogenicity of UJVIRA Results demonstrated biosimilarity between UJVIRA and Kadcyla in terms of efficacy, safety, how the body absorbs the medicine, and immunogenicity. Clinical breast cancer • 2022-06-15 • Phase III Randomized Trial | N = 168 | 82/100 | PMID 34955432 ↗ |
Kadcyla (Ado-Trastuzumab Emtansine) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.3200/unit (~$9.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $83.58 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $31.54 / mo | View logs ↓ |
Kadcyla (Ado-Trastuzumab Emtansine) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Kadcyla (Ado-Trastuzumab Emtansine) RxNorm Concept ID | 1658087 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.3200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $83.58 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $31.54 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 83.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Kadcyla (Ado-Trastuzumab Emtansine) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Kadcyla (Ado-Trastuzumab Emtansine) integrating DailyMed SPL (2026-04-01), CMS NADAC ($0.3200/unit), and 20 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Kadcyla (Ado-Trastuzumab Emtansine) community threads and patient logs by age, biological sex, dosage, and treatment duration.